Accepted for/Published in: JMIR Research Protocols
Date Submitted: Feb 21, 2025
Date Accepted: Sep 2, 2025
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The effects of a modified Mediterranean diet on gut microbiota and clinical outcomes in patients with metastatic colorectal cancer undergoing first-line chemotherapy with either anti-EGFR or anti-VEGF agent: protocol for a randomized pilot study
ABSTRACT
Background:
the gut microbiota is attracting increasing interest as an initiator of colorectal cancer. It has been observed that microbial imbalance in the gut and in cancer tissue is facilitated by a Western type diet, rich in meat, sugars, and refined grains, while a Mediterranean diet, rich in low saturated fat and fibers, promotes gut eubiosis, and results in reduced risk of developing colorectal cancer.
Objective:
to analyze and compare the gut microbiota of patients with metastatic colorectal cancer undergoing first-line chemotherapy +/- a biological agent (anti-EGFR or anti-VEGF), and receiving either a free standard Western diet, or a modified Mediterranean diet.
Methods:
this is a pilot non-drug, interventional prospective, randomized, controlled, single-center, open-label trial. Patients (n=40) will be randomized 1:1 to either a modified Mediterranean diet or a free Western type diet. Blood and fecal samples will be collected at baseline and control visits, for metagenomic and metabolomic analysis. The primary endpoint is the Firmicutes/Bacteroidetes ratio after completion of the third cycle of first-line chemotherapy (time T1). Secondary endpoints are: a) the percentage of patients experiencing gastrointestinal side effects at T1; b) the percentage of patients experiencing grade 3/4 gastrointestinal side effects at T1; c) changes in the Firmicutes/Bacteroidetes ratio, overall microbiome composition, and metabolome at T1, and after the sixth chemotherapy cycle (T2) versus baseline.
Results:
this pilot trial has received ethics approval on July 24th 2024. By January 2025, 7 participants have been recruited. The study will conclude with the visit at T2 for the last enrolled patient. Results are expected to be published in October 2028.
Conclusions:
this study has the potential to provide critical insights into the role of diet in modifying the gut microbiota, diminishing chemotherapy-related side effects, and possibly enhancing the therapeutic efficacy in metastatic colorectal cancer. Additionally, data may pave the way for future research in immunotherapy, potentially influencing both clinical practice and public health strategies. Clinical Trial: Clinicaltrial.gov NCT06794931 (https://clinicaltrials.gov/search?term=NCT06794931)
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.